Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life-Reference-Cited by-同舟云学术

Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

Published:2005 Issue:4-6 Volume:68 Page:520-525
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Tong Daniel K.H.,Cheng Carter W.N.,Ching Chan See,Ngor Wong Lai,Chow Louis W.C.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference22 articles.

1. Patient preferences for oral versus intravenous palliative chemotherapy.

2. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin

3. A study of quality of life in cancer patients receiving palliative chemotherapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature;Current Medical Research and Opinion;2016-08-09

2. Comparative Effectiveness of Two Metronomic Chemotherapy Schedules—Our Experience in the Preclinical Field;Cancer Investigation;2014-02-05

3. Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study;Oncology Research and Treatment;2014

4. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study;Cancer Chemotherapy and Pharmacology;2011-08-27

5. Anticancer oral therapy: Emerging related issues;Cancer Treatment Reviews;2010-12